Antibiotic use among children in British Columbia, Canada.

BACKGROUND In North America use of second-generation macrolides such as clarithromycin and azithromycin is popular due to favourable dosing and adverse event profiles. However, studies have also shown that use of second-generation macrolides promotes carriage of macrolide-resistant nasopharyngeal and oral streptococci. The present study was undertaken to characterize overall antibiotic use including macrolide antibiotics among children in British Columbia. METHODS Population-based data from British Columbia were analysed to determine antibiotic prescribing patterns for outpatient prescriptions from 1996 to 2003. Antibiotic prescription rates per 1000 children per year were evaluated by age (0-4, 5-9, 10-14, <15 years old), sex and physician diagnosis. RESULTS From 1996 to 2003, the overall BC prescription rate in children <15 years old decreased by one-third from 720 to 488 per 1000 children. The decrease in the rate of antibiotic consumption over time was seen across all age strata; however, the largest decrease (33%) was seen in children between the ages of 0-4 years. From 1996 to 2003, use of penicillins and cephalosporins decreased by 40% and 30%, respectively. This trend of decreasing antibiotic use with beta-lactams was seen in all age groups but the greatest decline was in the age group of 0-4 years (P value <0.05). During this time, macrolide use increased significantly (24%) from 102 to 126 per 1000 children (P value <0.001). This increase was seen in all age groups but again the greatest increase was seen in children of age between 0 and 4 years. Within the macrolides, use of erythromycin decreased by 72% (from 83 to 23 per 1000 children) while clarithromycin use increased by almost 3-fold (18-67 per 1000 children) and azithromycin use increased 81-fold (0.4-35 per 1000 children). In 2003, antibiotics were primarily being used for the treatment of upper respiratory tract infections, acute otitis media and bronchitis. CONCLUSIONS Overall antibiotic use has declined in children; however, there is increased use of macrolides which may have ramifications on macrolide-resistant streptococci, including Streptococcus pneumoniae and group A streptococci. A large proportion of antibiotic use in children is for upper respiratory tract infections and bronchitis, indications where there is a high likelihood that the aetiology is viral rather than bacterial.

[1]  M. Gerber.  Diagnosis and Treatment of Pharyngitis in Children , 2005, Pediatric Clinics of North America.

[2]  M. Jacobs.  Streptococcus pneumoniae: epidemiology and patterns of resistance. , 2004, The American journal of medicine.

[3]  F. Baquero,et al.  Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). , 2000, The Journal of antimicrobial chemotherapy.

[4]  P. Laippala,et al.  Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Susan S. Huang,et al.  Increased Use of Second-Generation Macrolide Antibiotics for Children in Nine Health Plans in the United States , 2004, Pediatrics.

[6]  A. Go,et al.  Reduction in antibiotic use among US children, 1996-2000. , 2003, Pediatrics.

[7]  Susan R. Johnson,et al.  Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .

[8]  David W Bates,et al.  Antibiotic treatment of children with sore throat. , 2005, JAMA.

[9]  K. Kelleher,et al.  Antibiotic prescribing by primary care physicians for children with upper respiratory tract infections. , 2002, Archives of pediatrics & adolescent medicine.

[10]  C. Sinaniotis,et al.  Community-acquired pneumonia in children , 2005, Current opinion in pulmonary medicine.

[11]  S. Straus,et al.  Interventions to improve antibiotic prescribing practices in ambulatory care. , 2005, The Cochrane database of systematic reviews.

[12]  G. Mccracken,et al.  Bacterial meningitis in children. , 2005, Lancet.

[13]  F. Baquero,et al.  Pharmacoepidemiological Analysis of Provincial Differences between Consumption of Macrolides and Rates of Erythromycin Resistance among Streptococcus pyogenes Isolates in Spain , 2002, Journal of Clinical Microbiology.

[14]  O. Cars,et al.  Reduction in outpatient antibiotic sales for pre-school children: interrupted time series analysis of weekly antibiotic sales data in Sweden 1992-2002. , 2005, The Journal of antimicrobial chemotherapy.

[15]  W. Kirch,et al.  Prescriptions of systemic antibiotics for children in Germany aged between 0 and 6 years , 2003, Pharmacoepidemiology and drug safety.

[16]  O. Vanderkooi,et al.  In Vitro Antimicrobial Susceptibilities of Streptococcus pneumoniae Clinical Isolates Obtained in Canada in 2002 , 2004, Antimicrobial Agents and Chemotherapy.

[17]  F. Marra,et al.  Per capita antibiotic consumption: how does a North American jurisdiction compare with Europe? , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  F. Baquero,et al.  Streptococcus pyogenes resistance to erythromycin in relation to macrolide consumption in Spain (1986-1997). , 2000, The Journal of antimicrobial chemotherapy.

[19]  L. Lix,et al.  Decrease in antibiotic use among children in the 1990s: not all antibiotics, not all children , 2004, Canadian Medical Association Journal.

[20]  R. Mera,et al.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. , 2005, Diagnostic microbiology and infectious disease.

[21]  B. Koes,et al.  Trends in prescribing antibiotics for children in Dutch general practice. , 2004, The Journal of antimicrobial chemotherapy.